Evidence map›Paper›PMID 34466340›Full record

ArticleIntractable & rare diseases research2021

Rare and intractable fibrodysplasia ossificans progressiva shows different PBMC phenotype possibly modulated by ascorbic acid and propranolol treatment.

Deborah Ribeiro Nascimento, Suzana Lopes Bomfim Balaniuc, Durval Batista Palhares, Adam Underwood, Marilene Garcia Palhares, Fabiana Alves, Francisco Oliveira Vieira, Elaine Maria Souza-Fagundes, Liane De Rosso Giuliani, Paula Cristhina Niz Xavier and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Intractable & rare diseases research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Deborah Ribeiro NascimentoUFMS/ Faculty of Medicine, Campo Grande, MS, Brazil.
Suzana Lopes Bomfim BalaniucUFMS/ Faculty of Medicine, Campo Grande, MS, Brazil.
Durval Batista PalharesUFMS/ Faculty of Medicine, Campo Grande, MS, Brazil.
Adam UnderwoodWalsh University, Division of Mathematics and Sciences, North Canton, OH, USA.
Marilene Garcia PalharesUFMS/ Faculty of Medicine, Campo Grande, MS, Brazil.
Fabiana AlvesUFMG/ Department of Physiology and Biophysics, Belo Horizonte, MG, Brazil.
Francisco Oliveira VieiraUFMG/ Department of Physiology and Biophysics, Belo Horizonte, MG, Brazil.
Elaine Maria Souza-FagundesUFMG/ Department of Physiology and Biophysics, Belo Horizonte, MG, Brazil.
Liane De Rosso GiulianiUFMS/ Faculty of Medicine, Campo Grande, MS, Brazil.
Paula Cristhina Niz XavierUFMS/ Faculty of Medicine, Campo Grande, MS, Brazil.
Helen Lima Del PuertoUFMG/ Department of Physiology and Biophysics, Belo Horizonte, MG, Brazil.
Robson Augusto Souza SantosUFMG/ Department of Physiology and Biophysics, Belo Horizonte, MG, Brazil.
Amy MilstedWalsh University, Division of Mathematics and Sciences, North Canton, OH, USA.
Jose Mauro BrumProcter & Gamble Health Care & Global Clinical Sciences, Mason, OH, USA.
Iandara Schettert SilvaUFMS/ Faculty of Medicine, Campo Grande, MS, Brazil.
Almir Sousa MartinsUFMS/ Faculty of Medicine, Campo Grande, MS, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fibrodysplasia Ossificans Progressiva (FOP) is a rare congenital intractable disease associated with a mutation in

Indexed as

FOPFOPCONgene expression modulationperipheral blood mononuclear cells

Identifiers

PMID34466340
PMCPMC8397826

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.